



Day 1 12:00 - 1:00pm	Registration and View Exhibits
1:00 pm	Opening Comments and Pre-Test
1:15 pm	Viral Hepatitis, Discovery of HCV and Its Natural History <ul style="list-style-type: none"> The evolving epidemiology of viral hepatitis around the world Manifestations of HCV and its relationship to HIV
2:00 pm	Hepatitis C: Update on Diagnostics <ul style="list-style-type: none"> Screening and diagnostic approaches by cohort Liver biopsy and newer, non-invasive diagnostic tools Hepatitis C: Update on Treatment <ul style="list-style-type: none"> 2020 AASLD/IDSA Guidelines Simplified Guidance
3:00 pm	Break and View exhibits
3:15 pm	Hepatitis B: Epidemiology, Natural History and Testing <ul style="list-style-type: none"> The epidemiology of the Hepatitis B infection Efficacies and opportunities in HBV testing and vaccination The growing relationship between HBV and HDV
3:45 pm	Anti-viral Therapies for HBV <ul style="list-style-type: none"> Early detection and treatment approaches Treating HCC in patients with Hepatitis B Guidance statements for co-infected patients
4:40pm	Delta Hepatitis and Hepatitis E Update from AASLD and EASL <ul style="list-style-type: none"> Worldwide perspective on and promising research studies Real world outcome studies on HDV and HEV Case Studies 1 and 2 –HIV/HCV Co-infection; Infections in persons who inject drugs.
5:10 pm	Presentation, Exhibitor Showcase and Reception
6:30 pm	Day 1 concludes
Day 2 7:30 am	Breakfast and View Exhibits
8:00 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> Staging, workup, and diagnosis of cirrhosis Medical care of the patient with end stage liver disease Liver Transplantation <ul style="list-style-type: none"> Listing criteria, MELD scores, Exceptions and the transplant process Case Study 3 – Cirrhosis and Encephalopathy
8:55 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> Screening diagnostic serum assays and imaging tests Diagnosis without histology Treatment and management options: Ablation, TACE and Surgery
9:25 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> Current FDA-Approved Therapies New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC Case Study 4– Diagnosis and Treatment of Hepatocellular Carcinoma
10:15 am	Break & View Exhibits
10:30 am	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis <ul style="list-style-type: none"> Epidemiology of PSC and Ursodiol and Antibiotic Treatments Predicting outcomes and Improving Survival in PSC patients Causes and Markers of PBC Ursodeoxycholic Acid (UDCA) and Obeticholic Acid



11:15 am	Viral Hepatitis Updates <ul style="list-style-type: none"> • The reemergence of Hepatitis A • Alcoholic liver disease • Emerging prevention and treatment approaches
11:45 am	SARS-COV-2 in Liver Disease <ul style="list-style-type: none"> • Effect of COVID on the liver and in cirrhotic patients • COVID-19 challenges for liver transplant recipients
12:15 pm	<i>Luncheon Presentation</i>
12:50pm	<i>Dessert and View Exhibits</i>
1:15 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Scoring and Management of Fatty Liver Disease • Raising awareness of LAL-D to avoid confusing symptoms with fatty liver disease • Staging and Management
2:10 pm	<i>Break & View Exhibits</i>
2:25 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH • Lifestyle changes as a therapy • Drugs in clinical development for NASH • PBC and NASH Updates from AASLD and EASL
3:30 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 3:45pm

Course Directors: Paul J. Pockros, MD - Scripps Clinic
Catherine Frenette, MD – Scripps Center for Cell and Organ Transplantation

Peer Review: Tracy Ander, DO- University of Louisville School of Medicine